Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children

Pediatric Infectious Disease Journal

Volumn 20, Issue 8, 2001, Pages 740-746

  Zangwill, Kenneth M ^a   Droge, Jessica ^a,d   Mendelman, Paul ^c   Marcy, S Michael ^a,b   Partridge, Susan ^a   Chiu, Chung Yin ^a   Jing, Jennie ^a   Chang, Swei Ju ^a   Cho, Iksung ^c   Ward, Joel I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c MEDIMMUNE   (United States)

^d Theracardia Inc   (United States)

Author keywords

Child; Immunization; Immunogenicity; Influenza; Intranasal trivalent influenza vaccine; Safety

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 0034881249     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200108000-00005     Document Type: Article

References (21)

1. Serious morbidity and mortality associated with influenza epidemics
2. The effect of influenza on hospitalization, outpatient visits, and courses of antibiotic in children
3. Influenza and the rates of hospitalization for respiratory disease among infants and young children
4. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
5. Biologic and immunologic characteristics of cold-adapted influenza virus
6. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: Nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25 degrees between recent H23N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/60
7. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children
8. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children
9. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults
10. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children
11. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
12. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/ Sydney) not contained in the vaccine
13. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
14. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
15. Influenzavirus infections in Seattle families, 1975-1979
16. Evaluation of live attenuated influenza vaccine in children 6-18 months of age: Safety, immunogenicity, and efficacy
17. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children
18. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
19. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults
20. Inactivated influenza vaccines
21. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children